Risk prediction of post-COVID conditions using NLRP3 and GSDMD markers in patients with bronchial asthma after COVID-19
Acta Biomedica Scientifica · 02.08.2026 · 11 (3) · 12-18
DOI: 10.29413/abs.2026-11.3.2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biomedica Scientifica, online erschienen am 02.08.2026. Verfasst von T. G. Lobova und 1 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
Background
One of the key factors in triggering the hyperinflammation cascade in patients with bronchial asthma and COVID-19 is the activation of NLRP3 cytosolic complexes and the GSDMD proteins by SARS-CoV-2, which are effector molecules for the lytic and inflammatory forms of pyroptosis.
Aim
To determine prognostic criteria for worsening of mild bronchial asthma following an infectious disease caused by SARS-CoV-2. Materials and Methods . In patients with mild, partially controlled bronchial asthma (n = 86), who were divided into 2 groups: asthma without COVID-19 (n = 34) and asthma following mild COVID-19 (n = 52), peripheral blood inflammatory markers were evaluated. The patients were examined immediately after recovery and confirmation of a negative SARS-COV-2 test result, and six months post-infection. The control group included conditionally healthy volunteers (n = 15) with no history of COVID-19. Pulmonary function was monitored by measuring FVCL, OFV1, and OFV1/FVCL. NLRP3 and gasdermin D inflammasomes were measured by enzyme-linked immunosorbent assay.
Results
The study revealed that in a number of patients with mild asthma, who had post-COVID conditions 6 months after COVID 19, there were elevated levels of NLRP3 inflammasome and gasdermin D (GSDMD), as well as a decreased pulmonary function, indicating a hyperinflammatory process. A predictive model for worsening of mild asthma after COVID-19 was developed: concurrent elevation of NLRP3 > 0.04 ng/ml and GSDMD > 0.38 ng/ml levels during the convalescence period serves as a marker of a high risk of post-COVID complications.
Conclusion
The role of NLRP3 and GSDMD in exacerbating the course of asthma after COVID-19 has been established, and predictive threshold values of biomarkers in this patient population have been identified.
Zitieren
APA
Lobova, T. G., & Vitkina, T. I. (2026). Risk prediction of post-COVID conditions using NLRP3 and GSDMD markers in patients with bronchial asthma after COVID-19. Acta Biomedica Scientifica, 11(3), 12-18. https://doi.org/10.29413/abs.2026-11.3.2
Vancouver
Lobova TG, Vitkina TI. Risk prediction of post-COVID conditions using NLRP3 and GSDMD markers in patients with bronchial asthma after COVID-19. Acta Biomedica Scientifica. 2026;11(3):12-18. doi:10.29413/abs.2026-11.3.2
BibTeX
@article{Lobova2026,
author = {Lobova, T. G. and Vitkina, T. I.},
title = {Risk prediction of post-COVID conditions using NLRP3 and GSDMD markers in patients with bronchial asthma after COVID-19},
journal = {Acta Biomedica Scientifica},
year = {2026},
volume = {11},
number = {3},
pages = {12--18},
doi = {10.29413/abs.2026-11.3.2}
}
EUVIMED